Anti-viral immuno therapeutic approaches for adult T-cell leukemia

我们之前的研究表明，激活htlv - i特异性t细胞反应的免疫方法可能会对ATL产生预防和治疗作用。为了验证这一概念并将其应用于临床，我们指出，在大鼠模型中，疫苗接种降低了原病毒载量，并且htlv - i携带者亚群表现出弱的htlv - i特异性t细胞反应和升高的原病毒载量。此外，我们在体内发现了先天免疫介导的抑制HTLV-I表达的机制。

Our previous studies suggested that immunological approaches to activate HTLV-I-specific T-cell response potentially induce prophylactic and therapeutic effects on ATL. In order to verify this notion and apply for bedside, we indicated that vaccination reduced proviral load in a rat model, and that a subpopulation of HTLV-I-carriers showed weak HTLV-I-specific T-cell response and elevated proviral load. Moreover, we discovered an innate immune-mediated mechanism suppressing HTLV-I expression in vivo.